The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 01 2021
12 01 2021
Historique:
received:
26
03
2020
accepted:
14
12
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Bacopa monnieri (Linn.) Wettst. has been used in traditional medicine as a drug to enhance and improve memory. In this regard, this study aims to provide B. monnieri's efficacy as a neuroprotective drug and as a nootropic against various neurological diseases. Literatures were collected, following Prisma guidelines, from databases, including Scopus, PubMed, Google Scholar, and Science Direct and were scrutinized using a quality scoring system. Means, standard deviations and 'n' numbers were extracted from the metrics and analyzed. Jamovi computer software for Mac was used to carry out the meta-analysis. The selected studies suggested that the plant extracts were able to show some improvements in healthy subjects which were determined in Auditory Verbal Learning Task, digit span-reverse test, inspection time task and working memory, even though it was not significant, as no two studies found statistically significant changes in the same two tests. B. monnieri was able to express modest improvements in subjects with memory loss, wherein only a few of the neuropsychological tests showed statistical significance. B. monnieri in a cocktail with other plant extracts were able to significantly reduce the effects of Alzheimer's disease, and depression which cannot be solely credited as the effect of B. monnieri. Although in one study B. monnieri was able to potentiate the beneficial effects of citalopram; on the whole, currently, there are only limited studies to establish the memory-enhancing and neuroprotective effects of B. monnieri. More studies have to be done in the future by comparing the effect with standard drugs, in order to establish these effects clinically in the plant and corroborate the preclinical data.
Identifiants
pubmed: 33436817
doi: 10.1038/s41598-020-80045-2
pii: 10.1038/s41598-020-80045-2
pmc: PMC7803732
doi:
Substances chimiques
Antidepressive Agents
0
Neuroprotective Agents
0
Nootropic Agents
0
Plant Extracts
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
596Références
Pan, P.-Y., Bölte, S., Kaur, P., Jamil, S. & Jonsson, U. Neurological disorders in autism: A systematic review and meta-analysis. Autism 20, 1362361320951370 (2020).
Moffitt, T. E., Belsky, D. W., Danese, A., Poulton, R. & Caspi, A. The longitudinal study of aging in human young adults: Knowledge gaps and research agenda. J. Gerontol. Ser. A 72, 210–215 (2017).
doi: 10.1093/gerona/glw191
Elliott, M. L. et al. Brain-age in midlife is associated with accelerated biological aging and cognitive decline in a longitudinal birth cohort. Mol. Psychiatry 20, 1–10 (2019).
Roodenrys, S. et al. Chronic effects of brahmi (Bacopamonnieri) on human memory. Neuropsychopharmacology 27, 279–281 (2002).
pubmed: 12093601
doi: 10.1016/S0893-133X(01)00419-5
Sivaramakrishna, C., Rao, C. V., Trimurtulu, G., Vanisree, M. & Subbaraju, G. V. Triterpenoid glycosides from Bacopamonnieri. Phytochemistry 66, 2719–2728. https://doi.org/10.1016/j.phytochem.2005.09.016 (2005).
doi: 10.1016/j.phytochem.2005.09.016
pubmed: 16293276
Limpeanchob, N., Jaipan, S., Rattanakaruna, S., Phrompittayarat, W. & Ingkaninan, K. Neuroprotective effect of Bacopamonnieri on beta-amyloid-induced cell death in primary cortical culture. J. Ethnopharmacol. 120, 112–117. https://doi.org/10.1016/j.jep.2008.07.039 (2008).
doi: 10.1016/j.jep.2008.07.039
pubmed: 18755259
Srimachai, S. et al. Bacopamonnieri extract increases rat coronary flow and protects against myocardial ischemia/reperfusion injury. BMC Complementary Altern. Med. 17, 117 (2017).
doi: 10.1186/s12906-017-1637-z
Menon, B. R., Rathi, M., Thirumoorthi, L. & Gopalakrishnan, V. Potential effect of Bacopamonnieri on nitrobenzene induced liver damage in rats. Indian J. Clin. Biochem. 25, 401–404 (2010).
pubmed: 21966114
pmcid: 2994561
doi: 10.1007/s12291-010-0048-4
Mallick, M. N. et al. Evaluation of anticancer potential of Bacopamonnieri L. against MCF-7 and MDA-MB 231 cell line. J. Pharm. Bioallied Sci. 7, 325 (2015).
pubmed: 26681894
pmcid: 4678980
doi: 10.4103/0975-7406.168038
Etzioni, D. A., Liu, J. H., Maggard, M. A. & Ko, C. Y. The aging population and its impact on the surgery workforce. Ann. Surg. 238, 170 (2003).
pubmed: 12894008
pmcid: 1422682
doi: 10.1097/01.SLA.0000081085.98792.3d
Farooqui, T. & Farooqui, A. A. Aging: An important factor for the pathogenesis of neurodegenerative diseases. Mech. Ageing Dev. 130, 203–215 (2009).
pubmed: 19071157
doi: 10.1016/j.mad.2008.11.006
Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: The amyloid cascade hypothesis. Science 256, 184–186 (1992).
pubmed: 1566067
doi: 10.1126/science.1566067
Christensen, K., Doblhammer, G., Rau, R. & Vaupel, J. W. Ageing populations: The challenges ahead. Lancet 374, 1196–1208 (2009).
pubmed: 19801098
pmcid: 2810516
doi: 10.1016/S0140-6736(09)61460-4
Prince, M. J., Prina, M. & Guerchet, M. Alzheimer Report 2013: Journey of Caring: An Analysis of Long-Term Care for Dementia 1–8 (Alzheimer’s Disease International, London, 2013).
Brimson, J. M., Prasanth, M. I., Plaingam, W. & Tencomnao, T. Bacopamonnieri (L.) wettst extract protects against glutamate toxicity and increases the longevity of Caenorhabditiselegans. J. Trad. Compl. Med. 10, 460–470. https://doi.org/10.1016/j.jtcme.2019.10.001 (2020).
doi: 10.1016/j.jtcme.2019.10.001
Holcomb, L. A. et al. Bacopamonniera extract reduces amyloid levels in PSAPP mice. J. Alzheimer’s Dis. 9, 243–251 (2006).
doi: 10.3233/JAD-2006-9303
Uabundit, N., Wattanathorn, J., Mucimapura, S. & Ingkaninan, K. Cognitive enhancement and neuroprotective effects of Bacopamonnieri in Alzheimer’s disease model. J. Ethnopharmacol. 127, 26–31 (2010).
pubmed: 19808086
doi: 10.1016/j.jep.2009.09.056
Saini, N., Singh, D. & Sandhir, R. Neuroprotective effects of Bacopamonnieri in experimental model of dementia. Neurochem. Res. 37, 1928–1937. https://doi.org/10.1007/s11064-012-0811-4 (2012).
doi: 10.1007/s11064-012-0811-4
pubmed: 22700087
Kamkaew, N., Norman Scholfield, C., Ingkaninan, K., Taepavarapruk, N. & Chootip, K. Bacopamonnieri increases cerebral blood flow in rat independent of blood pressure. Phytother. Res. 27, 135–138 (2013).
pubmed: 22447676
doi: 10.1002/ptr.4685
Chowdhuri, D. K. et al. Antistress effects of bacosides of Bacopamonnieri: Modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. Phytother. Res. 16, 639–645 (2002).
pubmed: 12410544
doi: 10.1002/ptr.1023
Dhanasekaran, M. et al. Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopamonniera. Phytother. Res. 21, 965–969. https://doi.org/10.1002/ptr.2195 (2007).
doi: 10.1002/ptr.2195
pubmed: 17604373
Chaudhari, K. S., Tiwari, N. R., Tiwari, R. R. & Sharma, R. S. Neurocognitive effect of nootropic drug Brahmi (Bacopamonnieri) in Alzheimer’s disease. Ann. Neurosci. 24, 111–122 (2017).
pubmed: 28588366
pmcid: 5448442
doi: 10.1159/000475900
Sinha, S. & Saxena, R. Effect of iron on lipid peroxidation, and enzymatic and non-enzymatic antioxidants and bacoside—a content in medicinal plant Bacopamonnieri L.. Chemosphere 62, 1340–1350 (2006).
pubmed: 16219336
doi: 10.1016/j.chemosphere.2005.07.030
Mathur, A. et al. Pharmacological investigation of Bacopamonnieri on the basis of antioxidant, antimicrobial and anti-inflammatory properties. J. Chem. Pharm. Res. 2, 191–198 (2010).
Shinomol, G. K. Bacopamonnieri modulates endogenous cytoplasmic and mitochondrial oxidative markers in prepubertal mice brain. Phytomedicine 18, 317–326 (2011).
pubmed: 20850955
doi: 10.1016/j.phymed.2010.08.005
Kumar, S. & Mondal, A. C. Neuroprotective, neurotrophic and anti-oxidative role of Bacopamonnieri on CUS induced model of depression in rat. Neurochem. Res. 41, 3083–3094 (2016).
pubmed: 27506204
doi: 10.1007/s11064-016-2029-3
Nemetchek, M. D., Stierle, A. A., Stierle, D. B. & Lurie, D. I. The Ayurvedic plant Bacopamonnieri inhibits inflammatory pathways in the brain. J. Ethnopharmacol. 197, 92–100 (2017).
pubmed: 27473605
doi: 10.1016/j.jep.2016.07.073
Saini, N., Singh, D. & Sandhir, R. Bacopamonnieri prevents colchicine-induced dementia by anti-inflammatory action. Metab. Brain Dis. 34, 505–518 (2019).
pubmed: 30604025
doi: 10.1007/s11011-018-0332-1
Murugaiyan, S. M. & Bhargavan, R. Bacopamonnieri alleviates aluminium chloride-induced anxiety by regulating plasma corticosterone level in Wistar rats. J. Basic Clin. Physiol. Pharmacol. https://doi.org/10.1515/jbcpp-2019-0379 (2020).
doi: 10.1515/jbcpp-2019-0379
pubmed: 32651984
Varshney, M., Gari, M. & Bansal, M. Effects of Bacopamonnieri and metformin on learning and memory in albino rats. IOSR J. Dent. Med. Sci. 19, 1–5 (2020).
Nestler, E. J. et al. Neurobiology of depression. Neuron 34, 13–25. https://doi.org/10.1016/s0896-6273(02)00653-0 (2002).
doi: 10.1016/s0896-6273(02)00653-0
pubmed: 11931738
Stahl, S. M. Antidepressant treatment of psychotic major depression: Potential role of the σ receptor. CNS Spectr. 10, 319–323 (2005).
pubmed: 15788959
doi: 10.1017/S1092852900022641
Knapp, D., Saiers, J. & Pohorecky, L. Observations of novel behaviors as indices of ethanol withdrawal-induced anxiety. Alcohol Alcohol. (Oxford, Oxfordshire) Supplement 2, 489 (1993).
Renoir, T., Pang, T. Y. & Lanfumey, L. Drug withdrawal-induced depression: Serotonergic and plasticity changes in animal models. Neurosci. Biobehav. Rev. 36, 696–726 (2012).
pubmed: 22037449
doi: 10.1016/j.neubiorev.2011.10.003
Monteiro, S. et al. An efficient chronic unpredictable stress protocol to induce stress-related responses in C57BL/6 mice. Front. Psychiatry 6, 6 (2015).
pubmed: 25698978
pmcid: 4313595
doi: 10.3389/fpsyt.2015.00006
Willner, P. Reliability of the chronic mild stress model of depression: A user survey. Neurobiol. Stress 6, 68–77 (2017).
pubmed: 28229110
doi: 10.1016/j.ynstr.2016.08.001
Willner, P. Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation. Psychopharmacology 134, 319–329 (1997).
doi: 10.1007/s002130050456
pubmed: 9452163
Willner, P. Chronic mild stress (CMS) revisited: Consistency and behavioural–neurobiological concordance in the effects of CMS. Neuropsychobiology 52, 90–110 (2005).
pubmed: 16037678
doi: 10.1159/000087097
Willner, P. The chronic mild stress (CMS) model of depression: History, evaluation and usage. Neurobiol. Stress 6, 78–93 (2017).
pubmed: 28229111
doi: 10.1016/j.ynstr.2016.08.002
Porsolt, R. D., Bertin, A. & Jalfre, M. Behavioral despair in mice: A primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229, 327–336 (1977).
pubmed: 596982
Can, A. et al. The mouse forced swim test. J. Vis. Exp. 20, e3638 (2012).
Borsini, F. & Meli, A. Is the forced swimming test a suitable model for revealing antidepressant activity?. Psychopharmacology 94, 147–160 (1988).
pubmed: 3127840
doi: 10.1007/BF00176837
O’Neill, K. A. & Valentino, D. Escapability and generalization: Effect on ‘behavioral despair’. Eur. J. Pharmacol. 78, 379–380 (1982).
pubmed: 7067732
doi: 10.1016/0014-2999(82)90043-7
Hyman, S. E. & Nestler, E. J. Initiation and adaptation: A paradigm for understanding psychotropic drug action. Am. J. Psychiatry 153, 151–151 (1996).
pubmed: 8561194
doi: 10.1176/ajp.153.2.151
Brimson, J. M. et al. Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression. Sci. Rep. 10, 9251–9251 (2020).
pubmed: 32514120
pmcid: 7280195
doi: 10.1038/s41598-020-65849-6
Brimson, J. M., Brimson, S., Chomchoei, C. & Tencomnao, T. Using Sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin. Therap. Targets https://doi.org/10.1080/14728222.2020.1805435 (2020).
doi: 10.1080/14728222.2020.1805435
Phillips, C. Brain-derived neurotrophic factor, depression, and physical activity: Making the neuroplastic connection. Neural Plasticity 2017, 7260130. https://doi.org/10.1155/2017/7260130 (2017).
doi: 10.1155/2017/7260130
pubmed: 28928987
pmcid: 5591905
Aydemir, C. et al. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1256–1260 (2006).
pubmed: 16647794
doi: 10.1016/j.pnpbp.2006.03.025
Calabrese, F. et al. Brain-derived neurotrophic factor: A bridge between inflammation and neuroplasticity. Front. Cell. Neurosci. 8, 430 (2014).
pubmed: 25565964
pmcid: 4273623
doi: 10.3389/fncel.2014.00430
Wu, Z., Wang, G., Wei, Y., Xiao, L. & Wang, H. PI3K/AKT/GSK3β/CRMP-2-mediated neuroplasticity in depression induced by stress. NeuroReport 29, 1256–1263 (2018).
pubmed: 30113922
doi: 10.1097/WNR.0000000000001096
Fan, C. et al. Curcumin protects against chronic stress-induced dysregulation of neuroplasticity and depression-like behaviors via suppressing IL-1β pathway in rats. Neuroscience 392, 92–106 (2018).
pubmed: 30268781
doi: 10.1016/j.neuroscience.2018.09.028
Brimson, J. M., Safrany, S. T., Qassam, H. & Tencomnao, T. Dipentylammonium binds to the sigma-1 receptor and protects against glutamate toxicity, attenuates dopamine toxicity and potentiates neurite outgrowth in various cultured cell lines. Neurotox. Res. 34, 263–272. https://doi.org/10.1007/s12640-018-9883-5 (2018).
doi: 10.1007/s12640-018-9883-5
pubmed: 29589276
Hashimoto, K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression. Prog. Neurobiol. 100, 15–29 (2013).
pubmed: 23044468
doi: 10.1016/j.pneurobio.2012.09.001
Hindmarch, I. & Hashimoto, K. Cognition and depression: The effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Human Psychopharmacol. Clin. Exp. 25, 193–200 (2010).
doi: 10.1002/hup.1106
Ishikawa, M. & Hashimoto, K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J. Receptor Ligand Channel Res. 3, 25–36 (2009).
Sindhu, P. et al. Evaluation of antidepressant activity of Bacopamonnieri in mice. Int. J. Pharmacy 4, 144–148 (2014).
Rauf, K. et al. Inhibitory effect of bacopasides on spontaneous morphine withdrawal induced depression in mice. Phytother. Res. 28, 937–939 (2014).
pubmed: 24243728
doi: 10.1002/ptr.5081
Suresh, M. S., Premsingh, T. S., Suresh, M. S. & Ashruji, S. P. Antidepressant in animal models of depression and study of cognitive property. GSC Biol. Pharm. Sci. 7, 064–076 (2019).
doi: 10.30574/gscbps.2019.7.3.0069
Sharma, L., Sharma, A., Gupta, G. L. & Bisht, G. S. Pharmacological evaluation of Bacopamonnieri extract against depressive like behavior induced by ethanol withdrawal in rats. Pharmacogn. J. 10, s48–s53. https://doi.org/10.5530/pj.2018.6s.9 (2018).
doi: 10.5530/pj.2018.6s.9
Müller, M. J. et al. Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: An open clinical trial. Psychiatry Res. 89, 275–280 (1999).
pubmed: 10708274
doi: 10.1016/S0165-1781(99)00100-6
Hazra, S., Kumar, S., Saha, G. K. & Mondal, A. C. Reversion of BDNF, Akt and CREB in hippocampus of chronic unpredictable stress induced rats: Effects of phytochemical, Bacopamonnieri. Psychiatry Investig. 14, 74–74 (2017).
pubmed: 28096878
doi: 10.4306/pi.2017.14.1.74
Banerjee, R., Hazra, S., Ghosh, A. K. & Mondal, A. C. Chronic administration of Bacopamonniera increases BDNF protein and mRNA expressions: A study in chronic unpredictable stress induced animal model of depression. Psychiatry Investig. 11, 297 (2014).
pubmed: 25110503
pmcid: 4124189
doi: 10.4306/pi.2014.11.3.297
Fukunaga, K. & Moriguchi, S. Sigma Receptors: Their Role in Disease and as Therapeutic Targets 201–211 (Springer, Berlin, 2017).
doi: 10.1007/978-3-319-50174-1_14
Bhuiyan, M. S., Tagashira, H. & Fukunaga, K. Sigma-1 receptor stimulation with fluvoxamine activates Akt–eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding. Eur. J. Pharmacol. 650, 621–628 (2011).
pubmed: 21044620
doi: 10.1016/j.ejphar.2010.10.055
Ji, L. L., Peng, J. B., Fu, C. H., Tong, L. & Wang, Z. Y. Sigma-1 receptor activation ameliorates anxiety-like behavior through NR2A-CREB-BDNF signaling pathway in a rat model submitted to single-prolonged stress. Mol. Med. Rep. 16, 4987–4993 (2017).
pubmed: 28791385
doi: 10.3892/mmr.2017.7185
Eraso-Pichot, A. et al. CREB decreases astrocytic excitability by modifying subcellular calcium fluxes via the sigma-1 receptor. Cell. Mol. Life Sci. 74, 937–950 (2017).
pubmed: 27761593
doi: 10.1007/s00018-016-2397-5
Zhang, S., Hong, J., Zhang, T., Wu, J. & Chen, L. Activation of sigma-1 receptor alleviates postpartum estrogen withdrawal-induced “Depression” through restoring hippocampal nNOS-NO-CREB activities in mice. Mol. Neurobiol. 54, 3017–3030 (2017).
pubmed: 27032391
doi: 10.1007/s12035-016-9872-8
Yagasaki, Y. et al. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J. Biol. Chem. 281, 12941–12949 (2006).
pubmed: 16522641
doi: 10.1074/jbc.M508157200
Ring, R. M. & Regan, C. M. Captodiamine, a putative antidepressant, enhances hypothalamic BDNF expression in vivo by synergistic 5-HT2c receptor antagonism and sigma-1 receptor agonism. J. Psychopharmacol. 27, 930–939 (2013).
pubmed: 23863923
doi: 10.1177/0269881113497614
Jadad, A. R. et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control. Clin. Trials 17, 1–12 (1996).
pubmed: 8721797
doi: 10.1016/0197-2456(95)00134-4
The jamovi project (2020). jamovi (Version 1.2) [Computer Software]. https://www.jamovi.org .
Stough, C. et al. The chronic effects of an extract of Bacopamonniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology 156, 481–484. https://doi.org/10.1007/s002130100815 (2001).
doi: 10.1007/s002130100815
pubmed: 11498727
Raghav, S., Singh, H., Dalal, P. K., Srivastava, J. S. & Asthana, O. P. Randomized controlled trial of standardized Bacopamonniera extract in age-associated memory impairment. Indian J. Psychiatry 48, 238–238. https://doi.org/10.4103/0019-5545.31555 (2006).
doi: 10.4103/0019-5545.31555
pubmed: 20703343
pmcid: 2915594
Calabrese, C. et al. Effects of a standardized Bacopamonnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial. J. Altern. Compl. Med. 14, 707–713. https://doi.org/10.1089/acm.2008.0018 (2008).
doi: 10.1089/acm.2008.0018
Stough, C. et al. Examining the nootropic effects of a special extract of Bacopamonniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother. Res. 24, 54–59. https://doi.org/10.1002/ptr (2008).
doi: 10.1002/ptr
Barbhaiya, H. C. et al. Efficacy and tolerability of BacoMind on memory improvement in elderly participants—a double blind placebo controlled study. J. Pharmacol. Toxicol. 3, 425–434. https://doi.org/10.3923/jpt.2008.425.434 (2008).
doi: 10.3923/jpt.2008.425.434
Morgan, A. & Stevens, J. Does Bacopamonnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J. Altern. Complement. Med. 16, 753–759. https://doi.org/10.1089/acm.2009.0342 (2010).
doi: 10.1089/acm.2009.0342
pubmed: 20590480
Mandal, A. K., Hedge, S. & Patki, P. S. A clinical study to evaluate the efficacy and safety of Bacopa caplets in memory and learning ability: A double blind placebo controlled study. Aust. J. Med. Herbal. 23, 122–125 (2011).
Peth-Nui, T. et al. Effects of 12-week Bacopamonnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers. Evid. Based Complem. Altern. Med. 1–10, 2012. https://doi.org/10.1155/2012/606424 (2012).
doi: 10.1155/2012/606424
Sathyanarayanan, V. et al. Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopamonniera) in healthy adults. Psychopharmacology 227, 299–306. https://doi.org/10.1007/s00213-013-2978-z (2013).
doi: 10.1007/s00213-013-2978-z
pubmed: 23354535
Kumar, N. et al. Efficacy of standardized extract Bacopamonnieri (bacognize) on cognative functions of medical students: A six-week, randomized placebo-controlled trial. Evid. Based Complement. Altern. Med. 1–8, 2016. https://doi.org/10.1155/2016/4103423 (2016).
doi: 10.1155/2016/4103423
Saraf, M. K., Prabhakar, S., Khanduja, K. L. & Anand, A. Bacopamonniera attenuates scopolamine-induced impairment of spatial memory in mice. Evid. Based Complement. Altern. Med. 1–10, 2010. https://doi.org/10.1093/ecam/neq038 (2011).
doi: 10.1093/ecam/neq038
Saraf, M. K., Anand, A. & Prabhakar, S. Scopolamine induced amnesia is reversed by Bacopamonniera through participation of kinase-CREB pathway. Neurochem. Res. 35, 279–287. https://doi.org/10.1007/s11064-009-0051-4 (2010).
doi: 10.1007/s11064-009-0051-4
pubmed: 19757037
Vollala, V. R., Upadhya, S. & Nayak, S. Effect of Bacopamonniera Linn. (brahmi) extract on learning and memory in rats: A behavioral study. J. Vet. Behav. 5, 69–74 (2010).
doi: 10.1016/j.jveb.2009.08.007
Zhou, Y., Peng, L., Zhang, W.-D. & Kong, D.-Y. Effect of triterpenoid saponins from Bacopamonniera on scopolamine-induced memory impairment in mice. Planta Med. 75, 568–574 (2009).
pubmed: 19214943
doi: 10.1055/s-0029-1185339
Sadhu, A. et al. Management of cognitive determinants in senile dementia of Alzheimer’s type: Therapeutic potential of a novel polyherbal drug product. Clin. Drug Investig. 34, 857–869. https://doi.org/10.1007/s40261-014-0235-9 (2014).
doi: 10.1007/s40261-014-0235-9
pubmed: 25316430
Cicero, A. F. et al. Short-term impact of a combined nutraceutical on cognitive function, perceived stress and depression in young elderly with cognitive impairment: A pilot, double-blind, randomized clinical trial. J. Prev. Alzheimer’s Dis. 4, 12–15. https://doi.org/10.14283/jpad.2016.10 (2017).
doi: 10.14283/jpad.2016.10
Zanotta, D., Puricelli, S. & Bonoldi, G. Cognitive effects of a dietary supplement made from extract of Bacopamonnieri, astaxanthin, phosphatidylserine, and vitamin E in subjects with mild cognitive impairment: A noncomparative, exploratory clinical study. Neuropsychiatr. Dis. Treat. 10, 225–230. https://doi.org/10.2147/NDT.S51092 (2014).
doi: 10.2147/NDT.S51092
pubmed: 24523587
pmcid: 3921088
Goswami, S. et al. Effect of Bacopamonnieri on cognitive functions in Alzheimer’s disease patients. Int. J. Collab. Res. Internal Med. Public Health 3, 285–293 (2011).
Hazra, S. et al. Evaluation of antidepressant activity of Bacopamonnieri in rat: A study in animal model of depression. Drug Discov. 2, 8–13 (2012).
Krishnakumar, A., Abraham, P. M., Paul, J. & Paulose, C. S. Down-regulation of cerebellar 5-HT2C receptors in pilocarpine-induced epilepsy in rats: Therapeutic role of Bacopamonnieri extract. J. Neurol. Sci. 284, 124–128 (2009).
pubmed: 19439326
doi: 10.1016/j.jns.2009.04.032
Ullah, I. et al. Attenuation of cisplatin-induced emetogenesis by standardized Bacopamonnieri extracts in the pigeon: Behavioral and neurochemical correlations. Planta Med. 80, 1569–1579 (2014).
pubmed: 25295673
doi: 10.1055/s-0034-1383121
Micheli, L. et al. Bacopamonnieri as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation. Phytother. Res. 34, 2331–2340. https://doi.org/10.1002/ptr.6684 (2020).
doi: 10.1002/ptr.6684
pubmed: 32236999